Qsymia Sales Reps Recruited For Experience With Metabolic Products
Vivus will benefit from downsizing at other firms, Chief Commercial Officer Mike Miller says. The company will aggressively seek formulary coverage, expects REMS to soothe payer concerns about appropriate use of the obesity product, he notes.
You may also be interested in...
The company’s vague corporate update includes plans to focus the Qsymia sales team on the most productive areas and potential cost-saving measures for a planned cardiovascular outcomes trial.
Assessments of obesity drugs should look at their effects in patients grouped by health status and FDA should expand the universe of secondary endpoints available to assess benefits, a group of stakeholders says.
Company reports several hundred prescribers have completed online training as part of the Risk Evaluation and Mitigation Strategy for the weight loss drug, which is moving toward a fourth-quarter entry into the marketplace.